Policy Positions for 2021 Rx Reform Bill
Infusion Providers Alliance2022-02-23T22:49:24+00:00The Infusion Providers Alliance (IPA) is the leading voice for [...]
About Infusion Providers Alliance
This author has not yet filled in any details.So far Infusion Providers Alliance has created 23 blog entries.
In the States
Infusion Providers Alliance2021-05-02T20:54:56+00:00The Infusion Providers Alliance (IPA) is the leading voice for [...]
IPA Weighs in on Step Therapy for Part B Drugs in Medicare Advantage
Infusion Providers Alliance2021-05-02T21:05:11+00:00The undersigned organizations, representing millions of Medicare beneficiaries with life-threatening, [...]
IPA Comments on MFN Model
Infusion Providers Alliance2021-01-27T13:59:49+00:00The Infusion Providers Alliance (IPA) appreciates the opportunity to comment [...]
IPA Statement on MFN Interim Final Rule
Infusion Providers Alliance2020-12-01T19:48:08+00:00Infusion Providers Alliance Responds to Most Favored Nation Drug Policy
Letter to Anthem
Infusion Providers Alliance2020-11-19T15:02:42+00:00New Requirement to Obtain Certain Drugs from CVS Specialty Pharmacy
Congress Should Continue Suspension of Medicare Sequester
Infusion Providers Alliance2021-02-12T16:53:41+00:00Suspension of the Medicare sequester is key to helping providers administer critical medicines during the COVID-19 pandemic.
Infusion Providers Alliance
Infusion Providers Alliance2020-10-13T16:43:36+00:00A new coalition of drug infusion providers has been established to advocate for policies that preserve patients’ access to infused medicines.
The Reliable Buy-And-Bill Distribution System
Infusion Providers Alliance2021-03-03T20:50:20+00:00Infusion centers and physician offices rely on the current, well-established “buy-and-bill” distribution system that has provided uninterrupted and reliable patient access to Part B infused drugs for decades.
Coupon Provision in Senate Finance Committee Drug Pricing Legislation
Infusion Providers Alliance2022-02-11T15:55:13+00:00The Infusion Providers Alliance supports the Senate Finance Committee’s overall goals of lowering prescription drug costs for patients. However, the alliance is concerned that a coupon provision included in “The Prescription Drug Pricing Reduction Act of 2019” could increase out-of-pocket costs and make treatment less accessible